Quick answer
What is Exenatide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Exenatide is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 12 from trials in people.
The literature search returned 2,890 records. This site keeps 12 of them, which is 0.42 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
A GLP-1 receptor agonist; the retrieved 1993 record reports exendin-4 as a high potency agonist at the GLP-1 receptor.[1]
Stated in the title of the cited 1993 Journal of Biological Chemistry paper.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 12 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 2,878 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. The Journal of biological chemistry (1993). pmid:8396143